494773-35-2

Basic information

• Product Name: 4-(2-BROMO-PHENYL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
• Synonyms: 4-(2-BROMO-PHENYL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;1-BOC-4-(2-Bromophenyl)piperazine;tert-Butyl 4-(2-bromophenyl)piperazine-1-carboxylate, 1-(2-Bromophenyl)-4-(tert-butoxycarbonyl)piperazine;t-Butyl 4-(2-bromo-phenyl)-piperazine-1-carboxylate;tert-butyl 4-(2-broMophenyl)piperazine-1-carboxylate;1-(2-Bromophenyl)-4-(tert-butyloxycarbonyl)piperazine
• CAS NO: 494773-35-2
• Molecular Formula: C₁₅H₂₁BrN₂O₂
• Molecular Weight: 341.24
• Product Categories: Organohalides
• Mol File: 494773-35-2.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 412.8±40.0 °C(Predicted)
• Appearance: /
• Density: 1.332
• PKA: 1.88±0.10(Predicted)
• CAS DataBase Reference: 4-(2-BROMO-PHENYL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-BROMO-PHENYL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(494773-35-2)
• EPA Substance Registry System: 4-(2-BROMO-PHENYL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(494773-35-2)

Safety Data

• Hazard Codes: Xi
• Safety Statements: 24/25
• Hazardous Substances Data: 494773-35-2(Hazardous Substances Data)

Usage

Description

4-(2-BROMO-PHENYL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is an organic compound that serves as an intermediate in the synthesis of pharmaceuticals, particularly in the production of Vortioxetine Hydrobromide. It is characterized by its chemical structure, which includes a bromophenyl group and a piperazine-1-carboxylic acid tert-butyl ester group, contributing to its reactivity and utility in the pharmaceutical industry.

Uses

Used in Pharmaceutical Industry:
4-(2-BROMO-PHENYL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is used as a key intermediate in the synthesis of Vortioxetine Hydrobromide, a drug prescribed for the treatment of depression. It plays a crucial role in the development of this medication due to its chemical properties that facilitate the formation of the final drug product.
Application Reason:
The use of 4-(2-BROMO-PHENYL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER in the synthesis of Vortioxetine Hydrobromide is driven by its ability to react with other compounds to form the desired active pharmaceutical ingredient. Its specific chemical structure allows for the creation of Vortioxetine Hydrobromide, which has been proven effective in managing depressive disorders.

Upstream product

• 88284-48-4 2-(trimethylsilyl)phenyl trifluoromethanesulfonate 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 583-55-1 1-Bromo-2-iodobenzene 
• 50606-33-2 piperazine-1-carboxylic acid phenyl ester 
• 75-65-0 tert-butyl alcohol 
• 170017-73-9 1-[1,1-Dimethylethoxycarbonyl]-4-(2-nitrophenyl)piperazine 
• 1493-27-2 ortho-nitrofluorobenzene 
• 170017-74-0 1-[1,1-dimethylethoxycarbonyl]-4-(2-aminophenyl)piperazine 
• 583-53-9 2,3-dibromobenzene 

Downstream Products

• 1073354-59-2 tert-butyl 4-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazine-1-carboxylate 
• 180698-18-4 1-([1,1'-biphenyl]-2-yl)piperazine 
• 1253936-10-5 1-{4-[2-(2-methoxy-pyrimidin-5-yl)phenyl]piperazin-1-yl}-2-pyrrolo[2,3-b]pyridin-1-yl-ethanone 
• 1253936-63-8 2-methoxy-5-(2-piperazin-1-yl-phenyl)pyrimidine 
• 1616296-14-0 4-(4-(2-bromophenyl)piperazin-1-yl)-2-cyclopropylquinazolin-6-amine 
• 1616296-13-9 4-(4-(2-bromophenyl)piperazin-1-yl)-2-cyclopropyl-6-nitroquinazoline 
• 1011-13-8 1-(2-bromophenyl)piperazine 
• 1567833-82-2 t-Butyl-3-[2-[4-[2-(4-benzyloxyphenyl)phenyl]piperazin-1-yl]ethoxy]propanoate 

Relevant articles and documents

Synthesis and structure–activity relationship studies of LLY-507 analogues as SMYD2 inhibitors

SET and MYND domain-containing protein 2 (SMYD2), a lysine methyltransferase, is reported to catalyze the methylation of lysine residues on histone and non-histone proteins. As a potential target for cancer therapy, there are several SMYD2 inhibitors are reported, LLY-507 as a cell-active inhibitor exhibits submicromolar potency against SMYD2 in several cancer cell lines. To know which structural fragment of LLY-507 is suitable for chemical modification, three sites are chosen for structure–activity relationship studies (SARs). Among our focused library, compounds 43 and 44 with amide link on site C showed reasonably improved potency indicating that modification on this fragment is more flexible and introduction of electrophilic warheads in this position might provide lysine-targeting covalent inhibitors for SMYD2.

PYRIDAZINONES AND METHODS OF USE THEREOF

Disclosed are compounds according to Formula (A), and related tautomers and pharmaceutical compositions. Also disclosed are therapeutic methods, e.g., of treating kidney diseases, using the compounds of Formula (A).

Synthesis of ortho -haloaminoarenes by aryne insertion of nitrogen-halide Bonds

A rapid and general access to ortho-haloaminoarenes has been developed by aryne insertion into N-chloramine, N-bromoamine, and N-iodoamine bonds via two complementary protocols harnessing fluoride-promoted 1,2-elimination of ortho-trimethylsilyl aryltriflates. Typically, electron-deficient N-chloramines effectively react with aryne intermediates generated at elevated temperature with CsF, while less stable N-haloamines are found more efficient under milder, TBAF-mediated aryne formation at room temperature. Both protocols demonstrate a good level of regioselectivity and functional group tolerance. Efforts to elucidate the mechanism of N-X insertion are also discussed. The practical value of this transformation is highlighted by rapid synthesis of novel analogues of the antipsychotic cariprazine.